Entecavir is an efficient inhibitor of HBV reverse transcriptase (RT) and widely used for therapy of chronic hepatitis B. Entecavir treatment of HBV patients with lamivudine-resistant viral strains, however, often fails, but the mechanism of cross-resistance development is not fully understood.
Methods
Using non-linear regression models, dose– response curves of cloned HBV strains from patients pre-treated with RT inhibitors were established in human hepatoma cell lines after transfection with HBV genomes containing HBV polymerase genes from patient isolates. 50% and 90% inhibitory concentrations (IC50 and IC90) and corresponding antiviral resistance factors (RF50 and RF90) were calculated.
Results
The entecavir dose–response curve of lamivudine-resistant HBV RT mutants rtM204 for the replication of HBV decreased less than expected with increasing drug dose. Remarkably, due to the fat dose–response curves, RF90 values against entecavir of samples with rtM204 substitutions were up to 30x higher than their RF50 values.
Conclusions
The unexpectedly high IC90 indicates a strong residual replication capacity of lamivudine-resistant HBV rtM204 variants under entecavir therapy, although IC50 values are initially within the therapeutic range of ente-cavir. This characteristic favours rapid selection of additional mutants with overt resistance against entecavir. Thus, the current phenotypic resistance assays should include determination of IC90.
References
1.
OttJ.J., StevensG.A., GroegerJ., WiersmaS.T.Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity.Vaccine2012; 30: 2212–2219.
2.
ChenC.J., YangH.I.Natural history of chronic hepatitis B REVEALed.J Gastroenterol Hepatol2011; 26: 628–638.
3.
PerrilloR.Benefits and risks of interferon therapy for hepatitis B.Hepatology2009; 49: S103–S111.
4.
European Association For The Study Of The Liver.EASL clinical practice guidelines: management of chronic hepatitis B virus infection.J Hepatol2012; 57: 167–185.
5.
GironesR., MillerR.H.Mutation rate of the hepadnavirus genome.Virology1989; 170: 595–597.
6.
ZoulimF., LocarniniS.Hepatitis B virus resistance to nucleos(t)ide analogues.Gastroenterology2009; 137: 1593–1608.
7.
PolS., LamperticoP.First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice.J Viral Hepat2012; 19: 377–386.
8.
TenneyD.J., RoseR.E., BaldickC.J.Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy.Hepatology2009; 49: 1503–1514.
9.
WarnerN., LocarniniS., KuiperM.The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro.Antimicrob Agents Chemother2007; 51: 2285–2292.
10.
YuenL.K., AyresA., LittlejohnM.SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B.Antiviral Res2007; 75: 64–74.
11.
QariS.H., RespessR., WeinstockH.Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1.J Clin Microbiol2002; 40: 31–35.
12.
BaldickC.J., EggersB.J., FangJ.Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response.J Hepatol2008; 48: 895–902.
13.
LangleyD.R., WalshA.W., BaldickC.J.Inhibition of hepatitis B virus polymerase by entecavir.J Virol2007; 81: 3992–4001.
14.
PetropoulosC.J., ParkinN.T., LimoliK.L.A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.Antimicrob Agents Chemother2000; 44: 920–928.
15.
VilletS., OllivetA., PichoudC.Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.J Hepatol2007; 46: 531–538.
16.
NassalM.The arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus assembly.J Virol1992; 66: 4107–4116.
17.
DelaneyW.E.4th, EdwardsR., ColledgeD.Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.Antimicrob Agents Chemother2001; 45: 1705–1713.
18.
ZoulimF., LocarniniS.Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance.Liver Int2013; 33Suppl 1: 116–124.
19.
GlebeD., GeipelA.Selected phenotypic assays used to evaluate antiviral resistance and viral fitness of hepatitis B virus and its variants.Intervirology2014; 57: 225–231.
20.
GeipelA., GlebeD., WillH., GerlichW.H.Hepatitis B virus rtI233V mutation and resistance to adefovir.N Engl J Med2014; 370: 1667–1668.
BaconT.H., LevinM.J., LearyJ.J., SariskyR.T., SuttonD.Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy.Clin Microbiol Rev2003; 16: 114–128.
23.
SeiferM., HamatakeR.K., ColonnoR.J., StandringD.N.In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.Antimicrob Agents Chemother1998; 42: 3200–3208.
24.
JonesS.A., MurakamiE., DelaneyW., FurmanP., HuJ.Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine.Antimicrob Agents Chemother2013; 57: 4181–4189.
25.
NassalM., RiegerA.A bulged region of the hepatitis B virus RNA encapsidation signal contains the replication origin for discontinuous first-strand DNA synthesis.J Virol1996; 70: 2764–2773.
26.
SampahM.E., ShenL., JilekB.L., SilicianoR.F.Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance.Proc Natl Acad Sci U S A2011; 108: 7613–7618.
